Innovation in life sciences is moving quickly, and regulation must keep pace. As technologies evolve and evidence is generated in new ways, regulatory frameworks need to remain robust, proportionate and responsive. This means recognising where flexibility and collaboration support safe and effective innovation.
In this strategy blog, Professor Joann Rhodes, Chief Executive of Health Innovation Research Alliance Northern Ireland (HIRANI), shares her perspectives on how the UK’s devolved health systems could be better used to support innovation in medicines and medical devices. She considers how adaptive regulation, strong partnerships and shared approaches to evidence generation may help developers navigate complex regulatory pathways, while maintaining the highest possible standards of safety, quality, and efficacy.
I am incredibly grateful to Professor Joann for sharing her wisdom and for contributing thoughtfully to the wider public discussion on how regulation, health systems and innovation can work together in the interests of patients.
Lawrence Tallon, Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA)
Guest blog: Professor Joann Rhodes
When referring to regulatory compliance there is a common assumption: that regulations whilst creating a common standard to ensure safety and quality, also stand for uniformity across a whole system. However, Regulations evolve and the UK system is anything but uniform.
The United Kingdom is not one place. It is four nations with different health systems, different research infrastructures, different industry clusters, different international relationships; and, in Northern Ireland’s case, a genuinely different regulatory jurisdiction. For medical devices that complexity is routinely framed as a headache. But what if we make the case that, if we’re brave enough to lean in, it is one of the most underexploited strategic assets in the UK life sciences ecosystem.
To unlock it, we need three things that don’t always sit alongside each other: regulation with real flexibility built in, creative and diverse regulatory science practitioners and place-based strategic partnerships that explore opportunities and go deeper than a visit and a handshake.
Regulation Isn’t Static. It Should Be a Living System.
The frameworks that were built for medicines and devices were designed for a world of static products. A small molecule drug that takes twelve years to develop, gets approved, and then sits on a shelf behaving predictably. You could write a rulebook for that world.
Excerpt from the official page. The original is authoritative. Continue reading at UK MHRA ↗